Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03063762
Title Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

renal cell carcinoma

Therapies

Atezolizumab + Obinutuzumab + RO6874281

Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.